Ariceum Therapeutics

We're #hiring a new Chemical Technical Assistant (m/w/d) in Berlin. Apply today or share this post with your network.

📢 News from #AriceumTherapeutics! 📢 Ariceum has announced a supply agreement with NorthStar Medical Radioisotopes, LLC for the therapeutic medical #radioisotope, Actinium-225 (Ac-225).   #NorthStar will provide Ariceum with non-carrier-added (n.c.a.), high purity, Ac-225, a rare and critical isotope that is in high demand, providing Ariceum with an additional clinical source of supply for its evolving pipeline development programs.   🌟 NorthStar's Ac-225 will be used by Ariceum to radiolabel its lead #radiopharmaceutical drug, #satoreotide, a first-in-class antagonist of the somatostatin receptor 2 (SSTR2). Manfred Ruediger, CEO at Ariceum commented "Satoreotide is the first Ac-225 labelled antagonist of the #SSTR2 receptor targeting #SCLC. The compound is scheduled to enter clinical development in the US as part of a transatlantic trial soon."   Saroreotide labelled with Lutetium-177 is currently progressing in a Phase 1b clinical study, targeting end stage-SCLC demonstrating its potential to significantly advance treatment options for hard-to-treat cancers.   Satoreotide presents a leap forward in Ariceum’s mission to deliver next-generation #radiotherapeutics for patients in need. For more details on this transformative collaboration, read the full announcement linked in the comments below 👇   #biotech #oncology #lifesciences #ATT001 #ATT002 #radiopharmaceuticals #IsotopeTechnology

🚨 Big strides being made by #AriceumTherapeutics in #radiopharmaceutical innovation! 📰 We're proud to announce the signing of a global supply agreement with Eckert & Ziegler SE for the medical #radionuclides, Actinium-225 (Ac-225) and Lutetium-177 (Lu-177). These radionuclides are central to the development of our targeted #radiopharmaceutical therapies and will be used to radiolabel our proprietary lead radiopharmaceutical drug #satoreotide. Satoreotide is a first-in-class antagonist of the somatostatin receptor 2 labelled with Ac-225 to enter clinical development in small cell lung cancer and Merkel Cell Carcinoma soon. 🤝 This collaboration is a significant step forward in accelerating #Ariceum’s novel targeted radiopharmaceutical pipeline programs, following limited global availability and increasing demand for Ac-225. Our CEO, Manfred Ruediger, commented "We are looking forward to working with the Eckert & Ziegler team to build a robust supply chain and to reliably deliver targeted theranostic treatments for patients with hard-to-treat cancers." For more information, read the full announcement linked in the comments below 👇. #biotech #oncology #lifesciences #satoreotide #ATT001 #ATT002 #radiopharmaceuticals #IsotopeTechnology

Handelsblatt named #Ariceum as the first of five German biotechs selected by leading venture capitalists, not invested in those companies, as offering the greatest potential in their specialist field.    The article describes #radiopharmaceuticals as one of the most promising treatment options tackling #cancer, with Holger Reithinger, Partner at #Forbion, citing #Ariceum’s very experienced management and research in areas of high unmet need.    Click https://bit.ly/49s8jx7 to read about all five biotechs!   #biotech #oncology #lifesciences #satoreotide #ATT001 #ATT002 #radiopharmaceutical

Are you attending the Targeted Radiopharmaceuticals Summit Europe in The Netherlands? Our COO, Greg Mullen, PhD, FRSC, will be participating in a workshop session exploring isotope selection to bring optimal treatment outcomes to patients, alongside presenting insights on expanding indications and selecting novel targets in the #radiopharmaceutical field. Find the details below to attend #Ariceum's workshop session and presentation at the #radiopharma-focused summit, held from 3rd-5th December in Amsterdam. Tuesday 3rd December 🕣 08:30 CET: Workshop - Meeting Your Match: Examining Physical Properties of Isotopes to Understand Their Effect Across Varying Disease Characteristics Thursday 5th December 🕒 15:00 CET: Assessing Future Directions for Addressing Unmet Medical Need by Expanding Indications & Selecting Novel Targets Get in touch to arrange a meeting! #biotech #oncology #lifesciences #ATT001 #ATT002 #radiopharmaceuticals

📰 Read #InVivo's recent article, titled 'Radiopharmaceutical Strategies Begin To Take Shape As Field Rolls Into 2025', by Melanie Senior, which delves into the recent flurry of multi-billion dollar deals in late 2023 and early 2024, and the recent clinical advancements in the #radiopharmaceutical field.   As radiopharmaceuticals become the new frontier in precision cancer therapy, Melanie explores the different target types, including #Ariceum's Iodine-123 labelled PARP inhibitor, currently being evaluated in a Phase 1 CITADEL-123 study for patients with recurrent #glioblastoma, an aggressive form of #braincancer.   Find out more about Ariceum's pipeline of #radiotherapeutics and its use of macrocyclic peptides which will be used in Ariceum's, “next three programs” confirmed by CBO of Ariceum, Serge SAGODIRA, in the article linked here: https://lnkd.in/eSTvY3NV   #biotech #oncology #lifesciences #ATT001 #ATT002 #radiopharmaceuticals #radiopharma

We're #hiring a new Chemical Technical Assistant (m/w/d) in Berlin. Apply today or share this post with your network.

🎧 Listen to the latest #optimumperspectives #podcast edition featuring our CMO, Germo Gericke, as he explores the importance of #lungcancer research and development this #LungCancerAwarenessMonth.   🎙️ Germo highlights "We believe that the mechanism of action of radioligand therapy, where you can attack the tumour wherever it has spread to the body, complements existing therapies and can leverage the proven technology of radiation in a state of disease where the classic radiation therapy with external beam no longer works."   💡 Listen to the full episode below to discover more about Germo's thoughts and expert knowledge of recent advancements in lung #cancer research, improving care standards, and #Ariceum's latest research with lead radiopharmaceutical drug #satoreotide, a first-in-class antagonist of the somatostatin receptor 2 (SSTR2), targeting extensive stage, small cell lung cancer #SCLC.   #biotech #oncology #lifesciences #ATT001 #ATT002 #radiopharmaceuticals #radiopharma

Meet the #Ariceum team at the 11th Annual Brisbane Cancer Conference, taking place this year from 28-29 November!   We look forward to networking 🤝 with fellow #cancer researchers to explore recent scientific, technological, nursing and medical advances in the diagnosis and treatment of malignant diseases.   Get in touch to arrange a meeting with Juergen Fleck, Head of Development Operations, and Jessica Klaver Preston, Clinical Trial Director, in Australia to learn more about our novel #radiopharmaceutical pipeline for hard-to-treat cancers, including our first-in-class proprietary peptide, #satoreotide, a first-in-class antagonist of the somatostatin receptor 2.   #biotech #oncology #lifesciences #ATT001 #ATT002 #radiopharmaceuticals #radiopharma

Exciting times ahead for #Ariceum as London Life Sciences Week (#LLSW) is fast approaching! 📅 Our CEO Manfred Ruediger will be attending the upcoming Jefferies London Healthcare Conference from 19-21 November alongside our CBO Serge SAGODIRA who will also be available for meetings in the City. The team looks forward to networking 🤝 with companies, investors, and VCs during the largest healthcare-dedicated conference in Europe, currently celebrating its 15th anniversary. 💡 Get in touch to set up a meeting to learn more about Ariceum’s novel #radiopharmaceutical pipeline. #JefferiesHealthcareConference #biotech #oncology #lifesciences #ATT001 #ATT002 #satoreotide #cancer #radiopharmaceuticals #radiopharma